文献速递儿童感染儿童呼吸

四价减毒活流感疫苗对丹麦2至6岁儿童流感相关住院和发病率的效果:模拟目标试验的全国性队列研究

Effectiveness of the quadrivalent live attenuated influenza vaccine against influenza-related hospitalisations and morbidity among children aged 2 to 6 years in Denmark: a nationwide cohort study emulating a target trial.
PubMed 文献 · Lancet Child Adolesc Health · 2023-10-25

该研究利用丹麦全国登记数据,模拟目标试验,比较接种四价减毒活流感疫苗(LAIV-4)与未接种的2-6岁儿童。研究支持LAIV-4在幼儿中提供中度保护。

要点

  • LAIV-4未显著减少呼吸道感染住院、喘息或哮喘住院或抗生素处方。

核心结论

  • 在流感A(H3N2)主导的季节,LAIV-4对2-6岁儿童流感相关医院接触提供中度保护,但对次要结局无显著减少。

研究设计与样本

  • 全国性队列研究,模拟目标试验;纳入丹麦2-6岁儿童,2021年10月1日至2022年1月15日接种LAIV-4者与未接种者按1:1匹配,随访至2022年5月31日。

主要发现

  • 在有和无严重流感危险因素的儿童中,疫苗有效性相似。

关键数值与推荐

  • 主要结局:流感相关医院接触和流感相关住院>12小时;次要结局:呼吸道感染住院、喘息或哮喘住院、抗生素处方。
  • 疫苗有效性计算公式为1 - IRR;使用泊松回归估计IRR和95%CI。

临床怎么用

  • 在2-6岁儿童中推广LAIV-4接种可减少流感相关医院接触,但对其他呼吸道结局的额外保护有限。

局限性

  • 观察性研究设计可能受未测量混杂影响;结果基于2021-2022季节以A(H3N2)为主,外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Scant evidence exists on the real-world effectiveness of quadrivalent live attenuated influenza vaccines (LAIV-4) in younger children. We aimed to assess the real-world effectiveness of LAIV-4 against influenza-related hospital contacts and admission and morbidity. METHODS: Using nationwide Danish health-care registries, we designed a cohort study that emulates a target trial, comparing LAIV-4 to no vaccination in children aged 2-6 years. Eligible children vaccinated from Oct 1, 2021, to Jan 15, 2022, were matched to unvaccinated controls in a 1:1 ratio according to demographic characteristics and risk groups for influenza, and followed-up until May 31, 2022. Primary study outcomes any hospital contact for influenza and influenza-related hospital admissions more than 12 h in duration, while hospital admission for respiratory tract infections, or for wheezing or asthma, and antibiotic prescriptions were evaluated as secondary outcomes. We estimated incidence rate ratios (IRRs) and 95% CIs using Poisson regression for each outcome. Vaccine effectiveness was calculated as 1 - IRR. FINDINGS: Among 308 520 Danish children aged 2-6 years, 95 434 vaccinated children were matched with 95 434 unvaccinated children who acted as controls. Receipt of LAIV-4 compared with no vaccination was associated with a reduced IRR of 0·36 (95% CI 0·27 to 0·46) and estimated vaccine effectiveness of 64·3% (53·6 to 72·6) against influenza-related hospital contacts (76 vs 210 events). The corresponding IRR and vaccine effectiveness against influenza-related hospital admissions were 0·63 (0·38 to 1·05) and 36·9% (-5·2 to 62·1; 24 vs 38 events), respectively. LAIV-4 was not associated with reductions in admission rates for respiratory tract infections (IRR 1·14, 95% CI 0·94 to 1·38), wheezing or asthma (1·04, 0·83 to 1·31), or antibiotic prescriptions for respiratory tract infections (0·97, 0·93 to 1·00). Vaccine effectiveness assessed across risk groups for influenza showed similar effectiveness in children with and without coexisting risk factors for severe influenza. INTERPRETATION: LAIV-4 offered moderate protection in younger children against influenza-related hospital contacts during a season dominated by influenza A(H3N2); however vaccination was not associated with reductions in secondary outcomes. This real-world study thereby supports trial evidence of moderate vaccine effectiveness of LAIV-4 against influenza-related outcomes when implementing broad vaccination schedules in younger children. FUNDING: Beckett-Fonden.

来源:Lancet Child Adolesc Health,查看原文。版权归原作者所有。

引用

  1. Kildegaard H, Lund LC, Pottegård A, et al. Effectiveness of the quadrivalent live attenuated influenza vaccine against influenza-related hospitalisations and morbidity among children aged 2 to 6 years in Denmark: a nationwide cohort study emulating a target trial. Lancet Child Adolesc Health. 2023. PMID: 37898144. doi:10.1016/S2352-4642(23)00225-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。